A Study of Intrathecal SHP611 in Children With Metachromatic Leukodystrophy
This study is investigating a new medicine called SHP611 for children diagnosed with Metachromatic Leukodystrophy (MLD). The main goal is to find out if SHP611, when injected directly into the fluid surrounding the brain and spinal cord, can help children keep their ability to walk and move around for a longer time. Researchers will also be observing how this medicine affects a child's movement and speech. Another important aim is to understand how well children tolerate the medicine and if there are any side effects. Children taking part in the study will receive SHP611 for around two years, with the possibility of continuing treatment for longer if the study shows it to be helpful.
Auf einen Blick
Ergebnisse
Ergebnisse dieser Studie
Veröffentlicht June 2024Die Ergebnisse dieser Studie wurden veröffentlicht.
Worum geht es in dieser Studie?
This study is looking at a new approach to treating Metachromatic Leukodystrophy (MLD) in children. MLD is a rare genetic condition that affects the brain and nervous system, making it difficult for children to move, speak, and learn over time. Currently, there isn't a cure, so researchers are constantly working to find treatments that can help.
The medicine being tested in this study is called SHP611. It's given through an injection directly into the fluid that surrounds the brain and spinal cord, which is known as 'intrathecal' delivery. This method is used because it helps the medicine reach the areas where it's needed most to hopefully slow down the progression of the disease.
The main purpose of this study is to see if SHP611 can help children with MLD keep their ability to move around independently for a longer period. The researchers will also be carefully monitoring other important aspects of a child's health, such as their ability to speak and their overall movement. It's also very important to find out if SHP611 is safe and well-tolerated by children.
Wichtige Erkenntnisse
- This study explores a new medicine (SHP611) for children with MLD.
- The medicine is given by injection into the spinal fluid.
- The main goal is to help children keep their ability to move for longer.
- Researchers will also check its effects on speech and safety.
- Participation lasts about two years, with possible extension.
Wer könnte berechtigt sein?
To join this study, children must have a formal diagnosis of Metachromatic Leukodystrophy (MLD). This means tests would have shown specific changes in their blood (low ASA activity) and urine (high sulfatides).
Children need to be within a specific age range, generally between 6 months and 6 years old, depending on their specific MLD symptoms. They must also have certain levels of symptoms. For some, this means having difficulty walking due to MLD by 2 and a half years old. Others might be very young (6 to under 18 months), showing very few symptoms, but having the same MLD gene changes as an older child in their family. Another group might be between 12 and under 18 months old, showing early MLD symptoms, but having previously been able to walk steadily.
Finally, parents or legal guardians must be able to follow the study schedule and must give their written permission for their child to take part.
Könnte diese Studie für Sie geeignet sein?
Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.
- Does my child have a confirmed MLD diagnosis?
- Is my child between 6 months and 6 years old (age varies by specific MLD symptoms)?
- Does my child meet certain criteria for MLD symptom severity or progression?
- Can I commit to following the study's schedule of appointments and procedures?
- Am I able to give informed consent for my child to participate?
Was beinhaltet die Teilnahme?
If your child takes part in this study, they will receive the study medicine, SHP611, for about two years. There might be a chance to continue receiving the medicine for a longer time after this initial period. The medicine will be given by injection directly into the fluid around the brain and spinal cord.
Throughout the study, there will be regular visits to the clinic so that doctors can carefully monitor your child's health, track their movement and speech, and check for any changes or side effects. These assessments help the research team understand how the medicine is working and how your child is responding. You'll be given a detailed schedule of visits and what each visit will involve.
Potenzielle Risiken und Vorteile
Locations (30)
- Los Angeles Biomedical Research Institute at Harbor-UCLAVerifizierte PostleitzahlTorrance, Vereinigte Staaten
- Kinderkrankenhaus ColoradoVerifizierte PostleitzahlAurora, Vereinigte Staaten
- Rare Disease Research, LLCVerifizierte PostleitzahlAtlanta, Vereinigte Staaten
- Ann & Robert H. Lurie Kinderkrankenhaus von ChicagoVerifizierte PostleitzahlChicago, Vereinigte Staaten
- University of Iowa Stead Family Children's HospitalVerifizierte PostleitzahlIowa City, Vereinigte Staaten
- Mayo Clinic - PPDSVerifizierte PostleitzahlRochester, Vereinigte Staaten
- New York University Langone Medical CenterVerifizierte PostleitzahlNew York, Vereinigte Staaten
- Cincinnati Kinderkrankenhaus Medizinisches ZentrumVerifizierte PostleitzahlCincinnati, Vereinigte Staaten
- Children's Hospital of PhiladelphiaVerifizierte PostleitzahlPhiladelphia, Vereinigte Staaten
- Children's Hospital of PittsburghVerifizierte PostleitzahlPittsburgh, United States
- University of UtahVerifizierte PostleitzahlSalt Lake City, Vereinigte Staaten
- Hospital Universitario Austral - PINNur StadtCiudad Autónoma Buenos Aires, Argentina
Häufige Fragen
What is Metachromatic Leukodystrophy (MLD)?
MLD is a rare genetic disease that affects the brain and nervous system, leading to problems with movement, speech, and other abilities over time.
What is SHP611?
SHP611 is the experimental medicine being tested in this study. It's hoped it can help children with MLD.
How is SHP611 given?
It's given as an injection into the fluid that surrounds the brain and spinal cord, similar to a lumbar puncture.
Wie lange wird mein Kind an der Studie teilnehmen?
Children will receive the medicine for about two years, and there might be an option for longer treatment.
Is this medicine available to everyone?
No, SHP611 is an investigational medicine, which means it's still being studied and is not yet available outside of clinical trials.
Wie Sie mehr erfahren können
Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.
Diskussion
Community-Diskussion
Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.